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The Impact of Frailty on Changes in Physical Function and 
Disease Activity Among Adults With Rheumatoid Arthritis
James S. Andrews,1  Laura Trupin,2 Katherine D. Wysham,3  Catherine L. Hough,1 Edward H. Yelin,2 and 
Patricia P. Katz2
Objective. Reduced physical function and frailty are common in rheumatoid arthritis (RA). However, relationships 
between frailty and changes in physical function and disease activity over time in RA are unknown. We tested whether 
frailty is a risk factor for worsening patient-reported physical function and disease activity in RA.
Methods. Adults from a longitudinal RA cohort (N = 124) participated. By using an established frailty definition, 
individuals with three or more of the following deficits were considered frail: 1) body mass index less than or equal to 
18.5, 2) low grip strength, 3) severe fatigue, 4) slow 4-m walking speed, and 5) low physical activity. Individuals with 
one to two or zero deficits were considered “pre-frail” or “robust,” respectively. Physical function and RA disease 
activity were assessed by the Health Assessment Questionnaire (HAQ) and Rheumatoid Arthritis Disease Activity 
Index (RADAI), respectively, at baseline and follow-up 2 years later. Regression analyses modeled associations of 
frailty status with change in HAQ and RADAI scores between baseline and follow-up with and without controlling for 
covariates. Associations of individual frailty components with change in HAQ and RADAI scores were also examined.
Results. Among adults with RA, baseline frailty status predicted significant increases, or worsening, in HAQ  
(β: 0.4; 95% confidence interval: 0.1-0.8; P < 0.01) but not RADAI scores (β: 0.5; 95% confidence interval: −0.4 to 1.5; 
P > 0.05) between baseline and follow-up in fully adjusted models. Fatigue was an important contributor to this effect.
Conclusion. Frailty may be an important risk factor for reduced physical function over time in RA. Future studies 
should address whether interventions to reduce frailty improve physical function in RA.
INTRODUCTION
Reduced physical function is common and is likely multifac-
torial among individuals with rheumatoid arthritis (RA) (1,2), and 
novel interventions are needed to improve physical function in 
these patients. Frailty, which is often defined as “a syndrome of 
decreased reserve and resistance to stressors…causing vulnera-
bility to adverse outcomes” (3), may play an important role in the 
development of reduced physical function in RA. A validated phe-
notype of frailty, defined by sarcopenia, weakness, fatigue, slow 
gait, and low physical activity (3), is an important risk factor for 
reduced physical function, poor clinical outcomes, and death in 
the general population of older adults (3,4). In addition, this frailty 
phenotype is common among individuals with various chronic dis-
eases, including congestive heart failure, chronic obstructive pul-
monary disease, and chronic kidney disease, and is associated 
with reduced physical function and poor clinical outcomes in these 
populations (5–9).
Recent studies have suggested that this frailty phenotype 
likely represents an important clinical entity, associated with var-
ious poor clinical outcomes, among individuals with rheumato-
logic diseases. For example, this frailty phenotype is common 
among women with lupus and is associated with worse physical 
function and mortality over time (10). Among individuals with RA, 
frailty is also common and is correlated cross‐sectionally with 
poorer patient‐reported physical function (11). The direction of 
effect cannot be discerned from cross‐sectional analyses, how-
ever, and the longitudinal relationship between baseline frailty 
status and change in physical function over time in RA has not 
been examined. In addition, the relationship between frailty sta-
tus and change in RA disease activity over time has not been 
studied.
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The aim of the current study is to address this gap in the 
literature by testing the hypothesis that baseline frailty status is 
an important risk factor for worsening patient‐reported physical 
function and RA disease activity over time among individuals in a 
longitudinal RA cohort. Identifying frailty as a unique and poten-
tially modifiable risk factor for reduced physical function and 
increased disease activity in RA would have the potential to facil-
itate the development of novel interventions targeting aspects of 
frailty to improve clinical outcomes for individuals with RA.
PATIENTS AND METHODS
Subjects. The sample for the present study is derived from 
a cohort developed at the University of California, San Francisco 
(UCSF) to study relationships between body composition and 
physical function in RA. Full details of this cohort have previously 
been published (11). Briefly, participants for the present cohort 
were drawn from a prior RA study, the UCSF RA panel study. 
Participants were recruited by telephone in 2009 and were eligible 
if they lived in the greater San Francisco Bay area and were willing 
to travel to UCSF. They were recruited for in‐person assessments 
(including measurement of body composition) at the UCSF Clinical 
and Translational Science Institute Clinical Research Center. RA 
diagnoses using the American College of Rheumatology (ACR) 
criteria were verified by a medical record review (12). Exclusion cri-
teria were non–English speaking, age less than 18 years, a current 
daily oral prednisone dose greater than 50 mg, current pregnancy, 
uncorrected vision problems that interfered with reading, and joint 
replacement within 1 year.
One hundred forty‐one individuals completed baseline study 
visits, including assessments of body composition, components 
of the Fried Frailty Assessment (described below), and measures 
of functioning. Follow‐up visits were intended to be approximately 
2 years later. The actual mean time between the baseline and fol-
low‐up visit was 2.3 (range: 1.7‐4.5) years; the median follow‐up 
time was 2.2 (interquartile range: 2.0‐2.4) years. Ninety percent 
of participants followed up within 2.9 years. Follow‐up data were 
available for 122 individuals. The final sample for the present study 
was composed of those participants with complete grip strength 
data at baseline (N = 124). The study was approved by the UCSF 
Committee on Human Research (approval 11‐05702).
Measures. Frailty. Frailty was assessed by using the method 
developed by Fried et al (3), which has been used previously in RA 
(11). Five physical deficits were assessed: 1) low body mass index 
(BMI), 2) low grip strength (adjusted for sex and BMI), 3) severe fa-
tigue, 4) slow 4‐m walking speed (adjusted for sex and height), and 
5) low physical activity. Individuals with three or more deficits were 
classified as “frail,” those with one or two deficits were classified as 
“pre‐frail,” and those with no deficits were classified as “robust.” BMI 
was calculated as weight/height2 (kg/m2). A BMI greater than or equal 
to 18.5 was classified as low. Grip strength of the participant’s dom-
inant hand was measured by using a hand‐held dynamometer (13). 
The fatigue severity subscale of the Multidimensional Assessment of 
Fatigue was used to assess fatigue; scores range from 0 to 10 (0 = no 
fatigue, and 10 = most‐severe fatigue) (14). A score of 7 or more was 
classified as severe fatigue (10,11). Participants in the lowest quintile 
of 4‐m walking speed (adjusted for sex and height) were classified 
as slow. Physical activity was assessed by self‐report with the long 
form of the International Physical Activity Questionnaire (IPAQ) (15). 
The IPAQ has been used and validated in a number of populations 
(16,17). The scoring protocol provides a cut point by which individu-
als’ weekly energy expenditure can be categorized as low, moderate, 
or high. Individuals who expended less than 600 metabolic equivalent 
task minutes per week were classified as having low physical activity 
(15,16,18).
Physical function. Self‐reported physical function was as-
sessed by using the Health Assessment Questionnaire (HAQ). 
Scores range from 0 to 3, with higher scores reflecting greater 
limitations (19).
RA disease activity. RA disease activity was assessed by us-
ing the Rheumatoid Arthritis Disease Activity Index (RADAI), a self‐
reported measure of disease activity in which scores range from 0 
to 10, with higher scores reflecting greater RA disease activity (20).
Other variables. Age was obtained from the baseline RA 
panel telephone interview. High‐sensitivity C‐reactive protein 
(hsCRP) was analyzed by nephelometry, and cyclic citrullinated 
peptide (CCP) immunoglobulin G was analyzed by immunoassay 
at a regional clinical laboratory. Glucocorticoid and tumor necro-
sis factor inhibitor medication use was assessed at the time of 
the visit. Blood samples were collected during study visits.
Statistical analysis. Primary analyses. Linear regres-
sion analyses were used to model the effect of baseline frailty 
status on change in HAQ and RADAI scores between baseline 
and follow‐up with and without adjusting for covariates (sex, 
age, baseline disease duration, hsCRP, CCP antibody level, 
and use of oral steroids). Because of skewedness, CRP values 
were logarithmically transformed to the normal distribution pri-
or to inclusion in regression analyses. Regression models were 
not adjusted for baseline HAQ or RADAI score because doing 
so risks inaccurately inflating regression coefficient estimates 
(21). In addition, to evaluate the contribution of individual frailty 
components to the overall relationships of baseline frailty sta-
tus with change in HAQ and RADAI scores between baseline 
and follow‐up, linear regression models were conducted, in 
which each of the five components of frailty were included as 
individual terms in the same model.
Nineteen individuals were missing at least one outcome 
measure score at follow‐up. Eleven individuals were missing 
follow‐up HAQ scores, six were missing follow‐up RADAI 
scores, and two were missing both scores. Differences in par-
ticipant characteristics between those missing and those not 
missing HAQ and/or RADAI follow‐up data were tested by using 
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either the t test, Kruskal‐Wallis test, or χ2 test. There were no 
statistically significant differences between participants 
missing versus participants not missing HAQ and/or RADAI 
scores at follow‐up (Supplementary Table 1). To account for 
the impact of missing data due to loss to follow‐up or lack 
of participation, we used multiple imputations with chained 
equations to model missing values, based on 10 replications 
(22–24), for the participants with complete baseline frailty data 
(N = 124). Here we report the results based on the use of 
multiple imputations, but in no instance were the results sub-
stantially different from those in the analyses in which missing 
values were not imputed.
Secondary analysis. To examine relationships of base-
line frailty status with HAQ and RADAI scores at follow‐up, 
linear regression analyses were used to model the effect 
of baseline frailty status on HAQ and RADAI scores at fol-
low‐up, rather than change in score between baseline and 
follow‐up, with and without adjusting for covariates (base-
line outcome score [HAQ or RADAI], sex, age, baseline 
disease duration, hsCRP, CCP antibody level, and use of 
oral steroids). HAQ and RADAI scores at follow‐up are used 
to assess physical function and disease activity status at 
follow‐up, which, like change over time, are also clinically 
relevant outcomes. Moreover, the relationships of baseline 
frailty status with HAQ and RADAI scores at follow‐up are 
also unknown and may differ from those of baseline frailty 
with changes in HAQ or RADAI scores over time. For exam-
ple, baseline frailty may not be associated with change the 
in HAQ or RADAI score over time, but it may nevertheless 
be associated with differences in HAQ or RADAI scores at 
follow‐up.
Sensitivity analysis. To examine whether advanced age af-
fects the primary relationships of interest, in preplanned sensitiv-
ity analyses, we examined whether the relationships of baseline 
frailty with change in HAQ and RADAI scores between baseline 
and follow‐up were sensitive to limiting the analysis to partic-
ipants age 64 years and younger. The number of participants 
age 64 years and younger did not permit analyzing frailty com-
ponents individually in this subgroup. In addition, the relatively 
small number of participants age 65 years and older (n = 35) did 
not permit analyzing either frailty category or frailty components 
in this subgroup. All statistical analyses were conducted by using 
Stata version 13.1 (StataCorp).
RESULTS
Subject characteristics. Participant baseline character-
istics are shown in Table  1. Overall, participants tended to be 
women in the sixth decade of life with long‐standing CCP anti-
body–positive RA and relatively low disease activity. Frailty was 
common in our cohort, with 10% of participants categorized 
as frail and 71% categorized as pre‐frail. Further details of the 
 distribution of frailty components are reported elsewhere (11). 
The average change in score between baseline and follow‐up for 
the entire cohort was 0.05 ± 0.4 and 0.1 ± 1.3 for the HAQ and 
RADAI measures, respectively.
Effect of baseline frailty status on change in physi-
cal function and disease activity between baseline and 
follow-up. Baseline frailty status was significantly associated 
with change in HAQ but not RADAI scores between baseline and 
follow‐up, even when adjusting for covariates (Table  2). Being 
frail, compared with being robust, was associated with an aver-
age 0.4‐point increase in the HAQ score between baseline and 
follow‐up, even when adjusting for covariates. In addition, being 
pre‐frail, compared with being robust, was associated with an 
average 0.2‐point increase in the HAQ score between baseline 
and follow‐up in the fully adjusted model. When follow‐up time (in 
years) was included as a covariate in the fully adjusted models, the 
overall trends remained the same (ie, baseline frailty status was 
associated with change in HAQ but not RADAI scores overt time) 
(data not shown).
Table 1. Participant baseline characteristics (N = 124)a
Variable Result
Age, y 58.0 ± 10.8
Female sex, % (n) 87 (108)
Disease duration, y 19.1 ± 10.7
CCP Ab positivity, % (n)b 63 (78)
hsCRP, mg/l 4.3 ± 6.6
Daily prednisone use, % (n) 32 (40)
TNF-α inhibitor use, % (n) 45 (56)
HAQ score 0.9 ± 0.6
RADAI score 2.4 ± 1.7
Frailty category, % (n)  
Frail 10 (12)
Pre-frail 71 (88)
Robust 19 (24)
Frailty components, % (n)c  
Low BMI 2 (3)
Low grip strength 65 (81)
High fatigue 24 (30)
Slow gait speed 6 (7)
Low physical activityd 31 (38)
Abbreviation: BMI, body mass index; CCP Ab, cyclic citrullinated 
peptide autoantibody; HAQ, Health Assessment Questionnaire; 
hsCRP, high-sensitivity C-reactive protein; RADAI, Rheumatoid 
Arthritis Disease Activity Index; TNF-α, tumor necrosis factor α.
a Values are mean ± SD unless otherwise indicated. 
b CCP Ab positivity is defined as a value of ≥ 20 units by en-
zyme-linked immunosorbent assay. 
c Frailty components are defined per Fried LP et al (3). 
d Low physical activity is based on International Physical Activity 
Questionnaire classification. 
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Effect of baseline frailty components on change in 
physical function and disease activity between baseline 
and follow-up. When the five frailty components were included 
in the same regression model as individual predictors of change 
in HAQ and RADAI scores between baseline and follow‐up, the 
presence of high fatigue was statistically, significantly associated 
Table 2. Complete model linear regression coefficients and 95% CIs for the effect of baseline frailty category on change in 
HAQ and RADAI scores between baseline and follow‐up among individuals with RA (N = 124)a
 
HAQ RADAI
Coefficient (95% CI) P Coefficient (95% CI) P
Frailty category     
Frail 0.4 (0.1 to 0.8)b 0.01b 0.5 (−0.4 to 1.5) 0.3
Pre-frail 0.2 (0.02 to 0.4)b 0.03b −0.2 (−0.8 to 0.4) 0.4
Robust Reference … Reference …
Age (y) −0.005 (−0.01 to 0.8) 0.2 −0.01 (−0.03 to 0.01) 0.4
Sex 0.05 (−0.2 to 0.3) 0.6 −0.02 (−0.7 to 0.7) 1.0
RA disease duration (y) 0.003 (−0.004 to 0.01) 0.4 0.007 (−0.02 to 0.03) 0.6
hsCRP (mg/l)c −0.06 (−0.1 to −0.004)b 0.04b −0.007 (−0.2 to 0.2) 0.9
Use of oral steroids (yes or no) 0.01 (−0.1 to 0.2) 0.8 −0.2 (−0.7 to 0.4) 0.5
CCP Ab titer (units) −0.0002 (−0.0009 to 
0.0005)
0.5 −0.0005 (−0.003 to 0.002) 0.3
Abbreviation: CCP Ab, cyclic citrullinated peptide auto-antibody; CI, confidence interval; HAQ, Health Assessment Ques-
tionnaire; hsCRP, high-sensitivity C-reactive protein; RA, rheumatoid arthritis; RADAI, Rheumatoid Arthritis Disease Activity 
Index.
a Increasing HAQ scores (0-3) and RADAI scores (0-10) reflect worse physical function and increased disease activity, re-
spectively. 
b P < 0.05. 
c Natural log-adjusted hsCRP. 
Table 3. Complete model linear regression coefficients and 95% CIs for the effect of baseline frailty components on 
change in HAQ or RADAI scores between baseline and follow‐up among individuals with RA (N = 124)a
 
HAQ RADAI
Coefficient (95% CI) P Coefficient (95% CI) P
Frailty component     
Low BMI (yes or no)b 0.5 (−0.03 to 0.9) 0.06 0.4 (−1.1 to 2.0) 0.6
Low grip strength (yes or no)b 0.1 (−0.04 to 0.3) 0.1 −0.3 (−0.8 to 0.2) 0.3
High fatigue (yes or no)b,c 0.2 (0.03 to 0.4)c 0.02c 0.03 (−0.6 to 0.6) 0.9
Slow gait speed (yes or no)b 0.2 (−0.1 to 0.5) 0.3 −0.3 (−1.2 to 0.8) 0.6
Low physical activity (yes or no)b,d −0.008 (−0.2 to 0.2) 0.9 0.2 (−0.3 to 0.8) 0.4
Age (y) −0.003 (−0.01 to 0.004) 0.4 −0.006 (−0.03 to 0.02) 0.6
Sex 0.02 (−0.2 to 0.1) 0.8 0.04 (−0.7 to 0.7) 0.9
RA disease duration (y) 0.003 (−0.003 to 0.01) 0.4 0.01 (−0.01 to 0.04) 0.4
hsCRP (mg/l)e −0.05 (−0.1 to 0.007) 0.08 0.05 (−0.1 to 0.3) 0.6
Use of oral steroids (yes or no) 0.04 (−0.1 to 0.2) 0.6 −0.2 (−0.7 to 0.4) 0.6
CCP Ab titer (units) −0.000009 (−0.0007 to 
0.0007)
1.0 −0.0006 (−0.003 to 
0.002)
0.6
Abbreviation: BMI, body mass index; CCP Ab, cyclic citrullinated peptide auto-antibody; CI, confidence interval; HAQ, 
Health Assessment Questionnaire; hsCRP, high-sensitivity C-reactive protein; RA, rheumatoid arthritis; RADI, Rheuma-
toid Arthritis Disease Activity Index.
a Increasing HAQ scores (0-3) and RADAI scores (0-10) reflect worse physical function and increased disease activity, 
respectively. 
b Frailty components are defined per Fried LP et al (3). 
c P < 0.05. 
d Low physical activity is based on International Physical Activity Questionnaire classification. 
e Natural log-adjusted hsCRP. 
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with an increase in the HAQ but not the RADAI score between 
baseline and follow‐up, even when adjusting for covariates 
(Table 3). The association between low grip strength and change 
in the HAQ score between baseline and follow‐up approached 
but did not reach statistical significance.
Secondary analysis: effect of baseline frailty status 
on physical function and disease activity score at fol-
low-up. Baseline frailty status was significantly associated with 
HAQ and RADAI scores at follow‐up, even when adjusting for 
covariates (Supplementary Table 2). Being frail, compared with 
being robust, was associated with an average 0.5‐point worse 
HAQ score and a 1.1‐point worse RADAI score at follow‐up, even 
when adjusting for covariates. In addition, being pre‐frail, com-
pared with being robust, was associated with an average 0.2‐
point worse HAQ score at follow‐up in the fully adjusted model.
Sensitivity analyses: relationship of baseline frailty 
with change in physical function and disease activity 
between baseline and follow-up among those age 64 
years and younger. Of the total cohort (N = 124), 89 (72%) 
were 64 years and younger. When the associations of baseline 
frailty status with changes in HAQ and RADAI scores between 
baseline and follow‐up were assessed only in participants age 
64 years and younger, the primary overall results remained 
unchanged (worse baseline frailty status was associated with an 
increase [ie, worsening] in HAQ but not RADAI scores between 
baseline and follow‐up). In fully adjusted models, being frail, 
compared with being robust, at baseline was associated with an 
average 0.4‐point increase (95% confidence interval: −0.0002 to 
0.8; P = 0.05) in the HAQ score between baseline and follow‐up. 
The association between baseline frailty status and change in 
RADAI score between baseline and follow‐up among those age 
64 years and younger was not statistically significant (data not 
shown).
DISCUSSION
In this cohort of men and women with established RA, we 
demonstrate significant effects of frailty on change in patient‐
reported physical function over time. Baseline frailty status pre-
dicted significant worsening in physical function, as measured by 
the HAQ, even when controlling for the effects of disease severity, 
disease duration, and medication use. These overall trends are 
unchanged when analyses are limited to participants age 64 years 
and younger, suggesting that effects of advanced age alone do 
not explain these relationships. In addition, fatigue appears to be 
a significant driver of the effect of baseline frailty status on change 
in physical function over time. These findings are, to our knowl-
edge, among the first in the literature to demonstrate that baseline 
frailty is associated with worsening physical function over time in 
individuals with RA, and they suggest that frailty may be an impor-
tant marker of individuals with RA who are at particular risk for 
increased physical disability over time.
The observed relationship of frailty status with change in 
physical function is likely to be clinically meaningful. The mini-
mum clinically important difference (MCID), which represents the 
minimum change needed to be clinically relevant, for the HAQ 
is a change of 0.22 points (25,26). We demonstrate that being 
frail, compared with being robust, among individuals with RA is 
associated with an average 0.4‐point increase in the HAQ score 
between baseline and follow‐up, even when adjusting for covar-
iates. Thus, the observed effect of frailty on change in the HAQ 
score over time exceeds by twofold, the threshold for a clinically 
important difference in the HAQ score.
The observed longitudinal relationship between frailty and 
change in patient‐reported physical function in RA adds to recent 
studies that have implicated frailty as an important risk factor for 
reduced physical function and increased adverse outcomes in 
patients with rheumatologic disease. Among women with lupus, 
being frail, compared with being robust, at baseline was associ-
ated with a 0.3‐point worse score on the Valued Life Activities (VLA) 
assessment, a patient‐reported assessment of physical function 
that is scored 0‐3, like the HAQ (27), and an approximately 7‐point 
worse score on the physical functioning subscale of the 36‐item 
Short Form Survey (MCID = 5) at the 2‐year follow‐up, even after 
adjusting for the effects of covariates, including age, lupus disease 
duration, lupus activity, and lupus damage (10). In that cohort, 
frailty was also associated with worse cognitive performance at the 
2‐year follow‐up and increased all‐cause mortality over an average 
follow‐up time of 7 years.
Moreover, we have previously shown that in cross‐sectional 
analyses of the same RA cohort as the present study, being frail, 
compared with being robust, was associated with a 0.44‐point 
worse VLA score, even when adjusting for the effects of RA dis-
ease activity, medication use, and pain. The magnitude of the 
effect of baseline frailty on change over time in physical perfor-
mance observed in the present study is comparable with that of 
these prior studies in lupus and RA. Thus, the observed relation-
ship between baseline frailty status and differences in physical 
function appears consistent and reproducible across multiple 
studies of not only RA but also lupus.
We did not observe a statistically significant relationship of 
baseline frailty status with change in the RADAI score between 
baseline and follow‐up. This finding suggests that the relation-
ship of baseline frailty status with change over time in physical 
function may differ from the relationship with change over time 
in RA disease activity. Moreover, although we did not observe a 
significant relationship between frailty and change over time in the 
RADAI score, we did observe a significant relationship between 
frailty and the RADAI score at follow‐up, even when adjusting for 
differences in baseline RADAI scores. Further studies are needed 
to explore and compare the relationships of baseline frailty status 
with change in the RADAI score over time and with the RADAI 
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score at follow‐up, but our observations suggest that these rela-
tionships may differ. Although baseline frailty may not be associ-
ated with change in disease activity (eg, RADAI score) over time, 
baseline frailty may still be associated with differences in disease 
activity at follow‐up in RA. Our findings may also reflect the overall 
relatively low RA disease activity present in our cohort, both at 
baseline and at follow‐up, which could limit our ability to identify 
a significant relationship between frailty and change in the RADAI 
score over time. Additional studies among cohorts with a wider 
range of disease activity may help elucidate these relationships.
Fatigue appears to play an important role in explaining the 
relationship between frailty and changes over time in physical 
function among those with RA. In our cohort, baseline fatigue was 
associated with significant worsening in the HAQ score between 
baseline and follow‐up. Fatigue is common among individuals with 
RA and often does not improve with RA‐specific pharmacother-
apy alone (28,29). By demonstrating that fatigue is an important 
contributor to the association between frailty and worse func-
tional outcomes in RA, this study further underscores the clinical 
relevance of addressing fatigue symptoms in caring for patients 
with RA and suggests a potential role of interventions that target 
fatigue in improving physical function over time in RA.
Given these results, frailty may represent a measurable risk 
factor to identify individuals with RA at greatest risk of becom-
ing disabled and may provide a unique opportunity to develop 
novel interventions aimed at improving clinical outcomes, such 
as physical performance, for individuals with RA. That baseline 
frailty status is associated with future physical performance in 
RA, even after adjusting for the effects of RA disease duration 
and severity, suggests that interventions specifically targeting 
aspects of frailty may help improve functional outcomes and pre-
vent physical disability for patients with RA when added to stand-
ard clinical pharmacotherapies that are focused on RA disease 
activity. For example, a recent trial of a pedometer intervention 
to increase walking in individuals with RA significantly improved 
participants’ physical activity and several patient‐reported out-
comes, including pain and fatigue, and trended toward improving 
disease activity, as assessed by the RADAI (30). Future studies 
will need to 1) further examine the ability of frailty status to identify 
patients with RA at increased risk of physical disability and poor 
RA‐disease control over time and 2) determine which aspects of 
frailty may be targeted most effectively to prevent physical disa-
bility and improve disease control for these patients.
This study has potential limitations. The lack of a non‐
RA control group is a potential limitation. In addition, the lack 
of a disease activity index that includes physician‐reported or 
laboratory data measures, such as the Clinical Disease Activ-
ity Index or the Disease Activity Score, to assess RA disease 
activity is another potential limitation, although the analyses 
were adjusted for C‐reactive protein (CRP). As discussed pre-
viously (11), the 17 participants who did not complete the grip 
strength assessment represent a potential limitation, further 
underscoring the logistical challenges around studying muscle 
strength in a clinical cohort. The lack of information on medical 
comorbidities, such as cognitive impairment or chronic heart 
or lung disease, is also a potential limitation. Lastly, because 
our cohort had, on average, relatively long‐standing and less 
symptomatic (as reflected in the RADAI score and CRP level) 
RA, it may limit generalizability to individuals with newly diag-
nosed or highly active RA.
There are also strengths of our study. The study is innova-
tive in that it is one of the first to identify frailty and, in particular, 
fatigue as a component of frailty, as a significant risk factor for 
worse patient‐reported physical function over time in RA. The 
study uses an established, validated measure of frailty that has 
been applied to various chronic disease populations. The men 
and women analyzed in the study compose a relatively large 
longitudinal cohort of individuals with physician‐documented 
RA. The use of validated, practical patient‐reported measures of 
physical function and disease activity is also a potential strength 
in that it facilitates conducting future studies by using these 
same measures in examining frailty and clinical outcomes in RA.
In conclusion, we observed that baseline frailty status 
is significantly associated with worse patient‐reported phys-
ical function over time in individuals with RA. The observed 
effects of frailty on physical function persisted after adjust-
ment for RA disease severity and duration, and the effects 
were clinically meaningful. Fatigue appears to be a primary 
contributor to the relationship between frailty and changes 
over time in physical function. These findings suggest that 
frailty may be an important and unique risk factor for physical 
disability in RA and that novel interventions targeting aspects 
of frailty may have the potential to improve functional out-
comes for these patients.
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